Vietnam Medicinal Materials reports sharp profit decline in Q3 2025

Vietnam Medicinal Materials Joint Stock Company announced a 55.61% decrease in profit after tax for Q3 2025 compared to Q3 2024. Profit after tax was VND 8,077,058,164 for Q3 2025 against VND 18,195,211,680 in Q3 2024. This decline is mainly attributed to a 38.33% reduction in Q3 2025 revenue from VND 456,699,409,545 to VND 330,149,798,379, reflecting the general economic situation.

Despite the revenue challenges, the company noted a decrease in financial expenses due to reduced current borrowings and a VND 1.3 billion decrease in selling expenses. This reduction in selling expenses was a result of focusing on wholesale channels, large agents, and hospitals, and minimizing retail channels.

However, general and administration expenses increased by VND 1.9 billion, largely driven by fluctuations in provisions for doubtful debts, which increased by VND 2.4 billion. The company maintains that no activities or events significantly affected its ability to continue as a going concern in Q3 2025.